Journal
ADDICTION BIOLOGY
Volume 16, Issue 1, Pages 116-119Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1369-1600.2010.00226.x
Keywords
Alcohol; dependence; dynorphin; nor-binaltorphimine (nor-BNI); self-administration; withdrawal
Categories
Funding
- National Institute on Alcohol Abuse and Alcoholism [AA08459, AA012602, AA014723]
- Pearson Center for Alcoholism and Addiction Research
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F32AA014723, R01AA008459, R37AA008459, R01AA012602] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Altered dynorphin opioid peptide systems contribute to increased ethanol self-administration during withdrawal following chronic alcohol exposure. We previously identified that the kappa-opioid receptor antagonist nor-binaltorphimine (nor-BNI) selectively reduced ethanol self-administration in dependent animals. The purpose of this study was twofold: (1) determine whether peripherally administered nor-BNI could reduce dependence-induced ethanol self-administration and (2) confirm the selective kappa-opioid effects of nor-BNI by administering it 24 hours prior to ethanol self-administration sessions occurring during acute withdrawal. Nor-BNI decreased ethanol self-administration in ethanol-dependent animals, with no effect in nondependent animals. Thus, the kappa-opioid/dynorphin system is a viable pharmacotherapeutic target for the treatment of alcoholism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available